Exendin-4 vs PACAP-27
Head-to-head comparison of Exendin-4 (Exendin-4 (synthetic exenatide)) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.
| Property | Exendin-4 | PACAP-27 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Exendin-4 (synthetic exenatide) | Pituitary Adenylate Cyclase-Activating Polypeptide-27 |
| Molecular Weight | 4186 Da | 3158 Da |
| Half-Life | 2.4 hours | minutes |
| Amino Acids | 39 | 27 |
| Typical Dose | 5-10 mcg twice daily | Research-only: 0.1-1 nmol/kg |
| Route | Subcutaneous | Intraperitoneal/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 1800 | 220 |
| Research Status | Clinical | Pre-clinical |
Exendin-4 Benefits
- ✓beta-cell survival
- ✓glucose-stimulated insulin secretion
- ✓reduced glucolipotoxicity
- ✓lowered HbA1c in clinical use
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Exendin-4 Dosing
5 mcg SC twice daily for 4 weeks|increase to 10 mcg SC twice daily if tolerated|research: 0.1-1 µM in vitro or 1-10 µg/kg in animals
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Exendin-4 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠injection-site reactions
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Research Overview
Exendin-4
Exendin-4 helped establish GLP-1 receptor biology in diabetes and remains a classic beta-cell protective peptide. Preclinical studies show reduced beta-cell apoptosis, improved insulin content, and better islet function under metabolic stress.
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.